La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sonoma Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che Sonoma Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 53.7% e 27.1% all'anno, mentre si prevede che l'EPS crescerà del 81.2% all'anno.

Informazioni chiave

53.7%

Tasso di crescita degli utili

81.2%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	19.4%
Tasso di crescita dei ricavi	27.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	15 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:O8Z - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2026	21	-2	N/A	1	2
3/31/2025	16	-3	N/A	-2	2
6/30/2024	13	-5	-3	-3	N/A
3/31/2024	13	-5	-2	-2	N/A
12/31/2023	12	-5	-5	-5	N/A
9/30/2023	12	-6	-4	-4	N/A
6/30/2023	13	-6	-5	-5	N/A
3/31/2023	13	-5	-6	-6	N/A
12/31/2022	13	-7	-5	-5	N/A
9/30/2022	13	-6	-5	-5	N/A
6/30/2022	13	-5	-5	-5	N/A
3/31/2022	13	-5	-4	-4	N/A
12/31/2021	12	-6	-4	-4	N/A
9/30/2021	15	-5	-3	-3	N/A
6/30/2021	17	-5	-2	-2	N/A
3/31/2021	19	-5	-4	-3	N/A
12/31/2020	21	-3	-6	-5	N/A
9/30/2020	20	-4	-7	-7	N/A
6/30/2020	19	-5	-8	-8	N/A
3/31/2020	18	-4	-5	-5	N/A
12/31/2019	18	-5	-4	-4	N/A
9/30/2019	19	-6	-5	-5	N/A
6/30/2019	19	-8	-8	-8	N/A
3/31/2019	19	-12	-12	-12	N/A
12/31/2018	18	-13	-12	-12	N/A
9/30/2018	18	-14	-12	-12	N/A
6/30/2018	17	-14	-11	-11	N/A
3/31/2018	17	-14	N/A	-12	N/A
12/31/2017	17	-12	N/A	-12	N/A
9/30/2017	16	-9	N/A	-11	N/A
6/30/2017	14	-9	N/A	-10	N/A
3/31/2017	13	-9	N/A	-8	N/A
12/31/2016	11	-9	N/A	-7	N/A
9/30/2016	10	-14	N/A	-8	N/A
6/30/2016	8	-16	N/A	-9	N/A
3/31/2016	9	-15	N/A	-9	N/A
12/31/2015	11	-13	N/A	-10	N/A
9/30/2015	12	-14	N/A	-8	N/A
6/30/2015	14	-10	N/A	-8	N/A
3/31/2015	14	-8	N/A	-7	N/A
12/31/2014	13	1	N/A	-6	N/A
9/30/2014	13	6	N/A	-5	N/A
6/30/2014	14	5	N/A	-5	N/A
3/31/2014	14	4	N/A	-5	N/A
12/31/2013	14	-6	N/A	-4	N/A
9/30/2013	14	-7	N/A	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che O8Z3 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che O8Z3 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che O8Z3 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di O8Z3 ( 27.1% all'anno) crescerà più rapidamente del mercato German ( 5.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di O8Z3 ( 27.1% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di O8Z3 è previsto essere elevato tra 3 anni

Sonoma Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

First quarter 2025 earnings released: US$0.067 loss per share (vs US$0.29 loss in 1Q 2024)

New major risk - Revenue and earnings growth

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Full year 2024 earnings released: US$0.53 loss per share (vs US$1.52 loss in FY 2023)

No longer forecast to breakeven

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings released: US$0.079 loss per share (vs US$0.62 loss in 3Q 2023)

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Insufficient new directors

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.81 loss in 3Q 2020)

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals, Inc. Plans to Relocate Remaining Manufacturing to Mexico

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita